Post-ASH, Onyx Has Grand Plans for Carfilzomib And Nexavar
This article was originally published in The Pink Sheet Daily
Following a buoyant meeting at ASH, Onyx outlines its next steps as it strives to move from being a "one-product" company, to filing an NDA for a second cancer drug by mid-2011.
You may also be interested in...
Small study of Onyx' proteasome inhibitor shows potential for replacing Velcade in combination with Revlimid and dexamethasone in newly diagnosed multiple myeloma patients.
Onyx's next-generation proteasome inhibitor shows a 24% response rate, 7.4 month durable response as a salvage therapy in multiple myeloma.
Spurred by the introduction of new and highly effective drugs that have vastly improved survival rates, the fast-moving myeloma market is becoming a very attractive sector in oncology